These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27300169)

  • 1. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
    Nagata T; Shimada Y; Sekine S; Moriyama M; Hashimoto I; Matsui K; Okumura T; Hori T; Imura J; Tsukada K
    Breast Cancer; 2017 Mar; 24(2):326-335. PubMed ID: 27300169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of NANOG and KLF4 for breast cancer.
    Nagata T; Shimada Y; Sekine S; Hori R; Matsui K; Okumura T; Sawada S; Fukuoka J; Tsukada K
    Breast Cancer; 2014 Jan; 21(1):96-101. PubMed ID: 22528804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
    Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
    Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imbalance in leptin-adiponectin levels and leptin receptor expression as chief contributors to triple negative breast cancer progression in Northeast India.
    Sultana R; Kataki AC; Borthakur BB; Basumatary TK; Bose S
    Gene; 2017 Jul; 621():51-58. PubMed ID: 28414093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Krüppel-Like Factor 4 and Its Activator APTO-253 Induce NOXA-Mediated, p53-Independent Apoptosis in Triple-Negative Breast Cancer Cells.
    Nakajima W; Miyazaki K; Asano Y; Kubota S; Tanaka N
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
    Sheng J; Xue X; Jiang K
    Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
    Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
    Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
    Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
    EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
    Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
    Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
    Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
    J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression analysis of iPS cell - inductive genes in esophageal squamous cell carcinoma by tissue microarray.
    Shimada Y; Okumura T; Sekine S; Moriyama M; Sawada S; Matsui K; Yoshioka I; Hojo S; Yoshida T; Nagata T; Fukuoka J; Tsukada K
    Anticancer Res; 2012 Dec; 32(12):5507-14. PubMed ID: 23225459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocan as a prognostic biomarker of triple-negative breast cancer.
    Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
    Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
    Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
    Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
    Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
    Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.